

Translation

PATENT COOPERATION TREATY

PCT/JP2003/014149

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PH-1941-PCT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/JP2003/014149	International filing date (day/month/year) 06 November 2003 (06.11.2003)	Priority date (day/month/year) 06 November 2002 (06.11.2002)
International Patent Classification (IPC) or national classification and IPC A01K 67/027, C12N 5/00		
Applicant CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.
<input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of _____ sheets.
3. This report contains indications relating to the following items: I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 06 November 2003 (06.11.2003)	Date of completion of this report 14 April 2004 (14.04.2004)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP2003/014149

I. Basis of the report

1. With regard to the elements of the international application:*

the international application as originally filed
 the description:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the claims:

pages _____, as originally filed
 pages _____, as amended (together with any statement under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the drawings:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the sequence listing part of the description:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
 the language of publication of the international application (under Rule 48.3(b)).
 the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in written form.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority in written form.
 furnished subsequently to this Authority in computer readable form.
 The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages _____
 the claims, Nos. _____
 the drawings, sheets/fig. _____

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP03/14149

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	2, 5, 8	YES
	Claims	1, 3, 4, 6, 7, 9	NO
Inventive step (IS)	Claims		YES
	Claims	1-9	NO
Industrial applicability (IA)	Claims	1-9	YES
	Claims		NO

2. Citations and explanations

Documents:

Document 1: WO, 02-43477, A1 (Central Institute for Experimental Animals), 6 June, 2002 (06.06.02)

Document 2: "The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow," (M. Urashima, et al.), Blood, 1997, Vol. 90, No. 2, pages 754-765

Explanation:

Document 1 describes that (1) human T cell lymphoma cell LM-2-JCK was transplanted into a NOG (Nod/Shi-scid, IL-2R γ KO) mouse, and (2) this model animal can be used as a method for screening the remedies for human lymphomas.

So, the subject matters of claims 1, 3, 4, 6, 7 and 9 do not appear to be novel.

Document 2 describes that human multiple myeloma cells such as U266 were transplanted into SCID mice indirectly through a spicule of a human fetus, to make model animals. Document 1 describes that (1) various cells can be efficiently transplanted into NOG mice, and (2) a human T cell lymphoma cell as a human hematopoietic organ tumor cell was successfully transplanted. So, a person skilled in the art could have easily selected the U266 described in document 2 as a human hematopoietic organ tumor cell to be transplanted. Furthermore, a person skilled in the art could have predicted the effect of this constitution from document 1.

So, the subject matters of claims 2, 5 and 8 do not appear to involve an inventive step.

The subject matters of claims 1-9 appear to be industrially applicable.